Nanomedicine-Based Neuroprotective Strategies in Patient Specific-iPSC and Personalized Medicine

被引:9
|
作者
Jang, Shih-Fan [1 ,6 ]
Liu, Wei-Hsiu [2 ,3 ,4 ]
Song, Wen-Shin [1 ,5 ]
Chiang, Kuan-Lin [1 ,6 ]
Ma, Hsin-I [2 ,3 ,4 ]
Kao, Chung-Lan [1 ,7 ]
Chen, Ming-Teh [1 ,8 ]
机构
[1] Natl Yang Ming Univ, Sch Med, Taipei 11221, Taiwan
[2] Triserv Gen Hosp, Dept Neurol Surg, Taipei 11490, Taiwan
[3] Natl Def Med Ctr, Taipei 11490, Taiwan
[4] Natl Def Med Ctr, Grad Inst Med Sci, Taipei 114, Taiwan
[5] Cheng Hsin Gen Hosp, Dept Neurosurg, Taipei 112, Taiwan
[6] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan
[7] Taipei Vet Gen Hosp, Dept Phys Med & Rehabil, Taipei 11217, Taiwan
[8] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei 11217, Taiwan
来源
关键词
induced pluripotent stem cells; personalized medicine; neurodegenerative; nanoparticles; PLURIPOTENT STEM-CELLS; SOLID LIPID NANOPARTICLES; CONTROLLED DRUG-DELIVERY; PLGA-BASED NANOPARTICLES; AGE-OF-ONSET; ALZHEIMERS-DISEASE; SOMATIC-CELLS; OXIDE NANOPARTICLES; HUNTINGTONS-DISEASE; PARKINSONS-DISEASE;
D O I
10.3390/ijms15033904
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In recent decades, nanotechnology has attracted major interests in view of drug delivery systems and therapies against diseases, such as cancer, neurodegenerative diseases, and many others. Nanotechnology provides the opportunity for nanoscale particles or molecules (so called Nanomedicine) to be delivered to the targeted sites, thereby, reducing toxicity (or side effects) and improving drug bioavailability. Nowadays, a great deal of nano-structured particles/vehicles has been discovered, including polymeric nanoparticles, lipid-based nanoparticles, and mesoporous silica nanoparticles. Nanomedical utilizations have already been well developed in many different aspects, including disease treatment, diagnostic, medical devices designing, and visualization (i.e., cell trafficking). However, while quite a few successful progressions on chemotherapy using nanotechnology have been developed, the implementations of nanoparticles on stem cell research are still sparsely populated. Stem cell applications and therapies are being considered to offer an outstanding potential in the treatment for numbers of maladies. Human induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state. Although the exact mechanisms underlying are still unclear, iPSCs are already being considered as useful tools for drug development/screening and modeling of diseases. Recently, personalized medicines have drawn great attentions in biological and pharmaceutical studies. Generally speaking, personalized medicine is a therapeutic model that offers a customized healthcare/cure being tailored to a specific patient based on his own genetic information. Consequently, the combination of nanomedicine and iPSCs could actually be the potent arms for remedies in transplantation medicine and personalized medicine. This review will focus on current use of nanoparticles on therapeutical applications, nanomedicine-based neuroprotective manipulations in patient specific-iPSCs and personalized medicine.
引用
收藏
页码:3904 / 3925
页数:22
相关论文
共 50 条
  • [41] Analysis of patient-specific NF1 variants leads to functional insights for Ras signaling that can impact personalized medicine
    Long, Ashlee
    Liu, Hui
    Liu, Jian
    Daniel, Michael
    Bedwell, David M.
    Korf, Bruce
    Kesterson, Robert A.
    Wallis, Deeann
    HUMAN MUTATION, 2022, 43 (01) : 30 - 41
  • [42] Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies
    Yokota, Etsuko
    Iwai, Miki
    Yukawa, Takuro
    Naomoto, Yoshio
    Haisa, Minoru
    Monobe, Yasumasa
    Takigawa, Nagio
    Fukazawa, Takuya
    Yamatsuji, Tomoki
    CANCER LETTERS, 2024, 588
  • [43] Got patient advocates? The value of patient advocate participation in a large research study to develop personalized risk-based breast cancer screening strategies
    Branch, Vernal
    Achenbach, Carolyn
    Ross, Kathleen G.
    Cohn, Wendy F.
    Yaffe, Martin D.
    Knaus, William A.
    Harvey, Jennifer A.
    CANCER RESEARCH, 2015, 75
  • [44] App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine-(TRACE)
    Doerner, Lorenz
    Grosse, Lucia
    Stange, Felix
    Hille, Hanni
    Kurz, Sylvia
    Becker, Hannes
    Volkmer, Sebastian
    Hippler, Melina
    Rieger, David
    Bombach, Paula
    Rieger, Johannes
    Weinert, Lina
    Svensson, Laura
    Anders, Carolin
    Cekin, Sila
    Paulsen, Frank
    Oener, Oeznur
    Ruhm, Kristina
    Malek, Holly Sundberg
    Moeller, Yonne
    Tatagiba, Marcos
    Wallwiener, Markus
    Eckert, Nils
    Escher, Pascal
    Pfeifer, Nico
    Forschner, Andrea
    Bauer, Armin
    Zips, Daniel
    Bitzer, Michael
    Malek, Nisar
    Gani, Cihan
    Tabatabai, Ghazaleh
    Renovanz, Mirjam
    NEURO-ONCOLOGY PRACTICE, 2024, 11 (03) : 336 - 346
  • [45] Evaluating treatment effect based on personal outcomes of specific interest (POSI): a personalized patient-reported outcome strategy
    Jaggumantri, Sravan
    Collet, Jean Paul
    McKellin, William
    Sawatzky, Richard
    Stockler, Sylvia
    van Karnebeek, Clara
    QUALITY OF LIFE RESEARCH, 2015, 24 : 138 - 138
  • [46] Personalized dynamic phantom of the right and left ventricles based on patient-specific anatomy for echocardiography studies - preliminary results
    Gomes-Fonseca, Joao
    Morais, Pedro
    Queiros, Sandro
    Veloso, Fernando
    Pinho, Antonio C. M.
    Fonseca, Jaime C.
    Correia-Pinto, Jorge
    Vilaca, Joao L.
    2018 IEEE 6TH INTERNATIONAL CONFERENCE ON SERIOUS GAMES AND APPLICATIONS FOR HEALTH (SEGAH '18), 2018,
  • [47] Human iPSC-based neurodevelopmental models of globoid cell leukodystrophy uncover patient- and cell type-specific disease phenotypes
    Mangiameli, Elisabeth
    Cecchele, Anna
    Morena, Francesco
    Sanvito, Francesca
    Matafora, Vittoria
    Cattaneo, Angela
    della Volpe, Lucrezia
    Gnani, Daniela
    Paulis, Marianna
    Susani, Lucia
    Martino, Sabata
    Di Micco, Raffaella
    Bachi, Angela
    Gritti, Angela
    STEM CELL REPORTS, 2021, 16 (06): : 1478 - 1495
  • [48] Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model
    Choi, In Young
    Lim, HoTae
    Estrellas, Kenneth
    Mula, Jyothi
    Cohen, Tatiana V.
    Zhang, Yuanfan
    Donnelly, Christopher J.
    Richard, Jean-Philippe
    Kim, Yong Jun
    Kim, Hyesoo
    Kazuki, Yasuhiro
    Oshimura, Mitsuo
    Li, Hongmei Lisa
    Hotta, Akitsu
    Rothstein, Jeffrey
    Maragakis, Nicholas
    Wagner, Kathryn R.
    Lee, Gabsang
    CELL REPORTS, 2016, 15 (10): : 2301 - 2312
  • [49] A single-cell based precision medicine approach using glioblastoma patient-specific models
    Park, James H.
    Feroze, Abdullah H.
    Emerson, Samuel N.
    Mihalas, Anca B.
    Keene, C. Dirk
    Cimino, Patrick J.
    de Lomana, Adrian Lopez Garcia
    Kannan, Kavya
    Wu, Wei-Ju
    Turkarslan, Serdar
    Baliga, Nitin S.
    Patel, Anoop P.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [50] A SINGLE-CELL BASED PRECISION MEDICINE APPROACH USING GLIOBLASTOMA PATIENT-SPECIFIC MODELS
    Feroze, Abdullah
    Park, James
    Emerson, Samuel
    Mihalas, Anca
    Keene, Dirk
    Cimino, Patrick
    Lopez, Adrian
    de Lomana, Garcia
    Kannan, Kavya
    Wu, Wei-Ju
    Turkarslan, Serdar
    Baliga, Nitin
    Patel, Anoop
    NEURO-ONCOLOGY, 2021, 23 : 6 - 7